Puregraft announced the publication of a clinical study demonstrating that Puregraft fat grafting significantly improved functional status and symptom relief at three and six months in patients with knee osteoarthritis.
Investigators randomized 30 patients into three groups: PG fat mixed with saline, PG fat mixed with low dose platelet rich plasma (PRP) and PG fat mixed with high dose PRP. Patients underwent a single intraarticular injection and were evaluated at three and six months. All treatment groups were effective in improving functional status and reducing symptoms, with a significant decrease observed at six months on all scores (except for low dose PRP using a standard index of knee function, and for high dose PRP using a standard index of knee stiffness). The majority of patients with initial abnormal flexion or extension of the knee improved at three months (no difference among groups) and this global improvement was observed at six months. There were no study treatment related adverse events.
Puregraft's filtration systems remove cell damaging free lipids, as well as white and red blood cells. Within 15 minutes, a physician can have access to a patient's own purified fat tissue.
Bradford Conlan, CEO of Puregraft, said, "Fat grafting remains one of the hottest growth segments in the reconstructive and regenerative surgery marketplace. This [study] continues to cement Puregraft as a standard for the autologous fat grafting."